These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 12474570)

  • 41. Coping and quality of life in one hundred and thirty five subjects with multiple sclerosis.
    Montel SR; Bungener C
    Mult Scler; 2007 Apr; 13(3):393-401. PubMed ID: 17439909
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cognitive deficits in multiple sclerosis patients with cerebellar symptoms.
    Valentino P; Cerasa A; Chiriaco C; Nisticò R; Pirritano D; Gioia M; Lanza P; Canino M; Del Giudice F; Gallo O; Condino F; Torchia G; Quattrone A
    Mult Scler; 2009 Jul; 15(7):854-9. PubMed ID: 19542264
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Reduced emotional reactivity to negative stimuli in multiple sclerosis, preliminary results].
    Di Bitonto L; Longato N; Jung B; Fleury M; Marcel C; Collongues N; de Seze J; Blanc F
    Rev Neurol (Paris); 2011 Nov; 167(11):820-6. PubMed ID: 21906769
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Multiple sclerosis and cognitive decline: is ApoE-4 a surrogate marker?
    Carmona O; Masuet C; Santiago O; Alía P; Moral E; Alonso-Magdalena L; Casado V; Arbizu T
    Acta Neurol Scand; 2011 Oct; 124(4):258-63. PubMed ID: 21208197
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cognitive training in MS: effects and relation to brain atrophy.
    Hildebrandt H; Lanz M; Hahn HK; Hoffmann E; Schwarze B; Schwendemann G; Kraus JA
    Restor Neurol Neurosci; 2007; 25(1):33-43. PubMed ID: 17473394
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Clinical features of 314 patients with relapsing-remitting multiple sclerosis].
    Nogales-Gaete J; Aracena R; Cepeda-Zumaeta S; Eloiza C; Agurto P; Díaz V; Labbé S; Martínez S; Flores J; Araya C
    Rev Med Chil; 2014 May; 142(5):559-66. PubMed ID: 25427011
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A brief neuropsychological screening test battery for cognitive dysfunction in Brazilian multiple sclerosis patients.
    Negreiros MA; Mattos P; Landeira-Fernandez J; Paes RA; Alvarenga RP
    Brain Inj; 2008 May; 22(5):419-26. PubMed ID: 18415722
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Patient-reported adverse effects of high-dose intravenous methylprednisolone treatment: a prospective web-based multi-center study in multiple sclerosis patients with a relapse.
    Jongen PJ; Stavrakaki I; Voet B; Hoogervorst E; van Munster E; Linssen WH; Sinnige LG; Verhagen WI; Visser LH; van der Kruijk R; Verheul F; Boringa J; Heerings M; Gladdines W; Lönnqvist F; Gaillard P
    J Neurol; 2016 Aug; 263(8):1641-51. PubMed ID: 27272956
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neuropsychological rehabilitation does not improve cognitive performance but reduces perceived cognitive deficits in patients with multiple sclerosis: a randomised, controlled, multi-centre trial.
    Mäntynen A; Rosti-Otajärvi E; Koivisto K; Lilja A; Huhtala H; Hämäläinen P
    Mult Scler; 2014 Jan; 20(1):99-107. PubMed ID: 23804555
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Short-term safety of pulse steroid therapy in multiple sclerosis relapses.
    Shaygannejad V; Ashtari F; Alinaghian M; Norouzi R; Salari M; Fatehi F
    Clin Neuropharmacol; 2013; 36(1):1-3. PubMed ID: 23334067
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Recovery following acute exacerbations of multiple sclerosis: from impairment to quality of life.
    Bethoux F; Miller DM; Kinkel RP
    Mult Scler; 2001 Apr; 7(2):137-42. PubMed ID: 11424634
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical impact of intravenous methylprednisolone in attacks of multiple sclerosis.
    Nos C; Sastre-Garriga J; Borràs C; Río J; Tintoré M; Montalban X
    Mult Scler; 2004 Aug; 10(4):413-6. PubMed ID: 15327039
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Methylprednisolone-induced Toxic Hepatitis After Intravenous Pulsed Therapy for Multiple Sclerosis Relapses.
    Ferraro D; Mirante VG; Losi L; Villa E; Simone AM; Vitetta F; Federzoni L; Nichelli PF; Sola P
    Neurologist; 2015 Jun; 19(6):153-4. PubMed ID: 26075468
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Differential treatment effect on measures of neurologic exam, functional impairment and patient self-report in multiple sclerosis.
    Hoogervorst EL; Kalkers NF; van Winsen LML ; Uitdehaag BM; Polman CH
    Mult Scler; 2001 Oct; 7(5):335-9. PubMed ID: 11724450
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Health-related quality of life and its relationship to cognitive and emotional functioning in multiple sclerosis patients.
    Benito-León J; Morales JM; Rivera-Navarro J
    Eur J Neurol; 2002 Sep; 9(5):497-502. PubMed ID: 12220381
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Depression and cognitive impairment in disability-free early multiple sclerosis.
    Haase CG; Tinnefeld M; Lienemann M; Ganz RE; Faustmann PM
    Behav Neurol; 2003; 14(1-2):39-45. PubMed ID: 12719637
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Peripheral blood cell immunomarkers in the course of methylprednisolone treatment of multiple sclerosis relapses.
    Michałowska-Wender G; Wender M
    Folia Neuropathol; 2008; 46(2):134-8. PubMed ID: 18587707
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Moral Cognition and Multiple Sclerosis: A Neuropsychological Study.
    Realmuto S; Dodich A; Meli R; Canessa N; Ragonese P; Salemi G; Cerami C
    Arch Clin Neuropsychol; 2019 May; 34(3):319-326. PubMed ID: 29850776
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fatigue, emotional functioning, and executive dysfunction in pediatric multiple sclerosis.
    Holland AA; Graves D; Greenberg BM; Harder LL
    Child Neuropsychol; 2014; 20(1):71-85. PubMed ID: 23216329
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of methylprednisolone treatment on the expression of macrophage inflammatory protein 3alpha and B lymphocyte chemoattractant in serum of multiple sclerosis patients.
    Michałowska-Wender G; Losy J; Biernacka-Łukanty J; Wender M
    Pharmacol Rep; 2008; 60(4):549-54. PubMed ID: 18799824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.